Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
41 results about "Interleukin-4 receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The interleukin 4 receptor is a type I cytokine receptor. IL4R is its human gene.
Storage stable powder compositions of interleukin-4 receptor
InactiveUS6896906B2Good chemical stabilityImprove physical stabilityPowder deliveryPeptide/protein ingredientsWhite blood cellPhysical chemistry
The present invention provides storage stable dry powder compositions of IL-4R. The powder compositions demonstrate superior chemical and physical stability over their solution counterparts, particularly upon storage under varying conditions of temperature and humidity. Moreover, the powders, as prepared, possess good aerosol properties, which are maintained upon storage.
Owner:NOVARTIS FARMA
Antibodies to Interleukin-4 receptors and uses thereof
InactiveUS7317090B2Peptide/protein ingredientsMicroorganism based processesAntibodyInterleukin-4 receptor
Owner:IMMUNEX CORP
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor
ActiveUS20140356372A1Prevention and reduction of severityImprove efficacyPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsRegimenSeverity/Intensity
The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and / or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4Rα) antagonist such as an anti-IL-4Rα antibody.
Owner:REGENERON PHARM INC
Antagonists of interleukin-2 receptor
ActiveUS9428567B2Reduce interactionPeptide/protein ingredientsDepsipeptidesInterleukin IIMutant protein
Novel human interleukin-2 (IL-2) muteins or variants thereof, and nucleic acid molecules and variants thereof are provided. Methods for producing these muteins as well as methods for stimulating the immune system of an animal are also disclosed. In addition, the invention provides recombinant expression vectors comprising the nucleic acid molecules of this invention and host cells into which expression vectors have been introduced. Pharmaceutical compositions are included comprising a therapeutically effective amount of a human IL-2 mutein of the invention and a pharmaceutically acceptable carrier. The IL-2 muteins can be used in pharmaceutical compositions for use in treatment of cancer and in stimulating the immune response.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Methods for treating or preventing asthma by administering an IL-4R antagonist
ActiveUS9574004B2Reduce and eliminate dependenceMaintaining the patient's background therapyAntimycoticsAntipyreticAntagonistAntibody
Owner:SANOFI BIOTECH SAS +1
Methods for treating eosinophilic esophagitis by administering an IL-4R inhibitor
Owner:REGENERON PHARM INC
Anti-human interleukin-4 receptor alpha monoclonal antibody, preparation method and applications thereof
The present invention belongs to the field of antibodies, and more particularly discloses a recombinant anti-human hIL-4R[alpha] monoclonal antibody, a preparation method and applications thereof. According to the present invention, the anti-human hIL-4R[alpha] monoclonal antibody can specifically bind to human hIL-4R[alpha], can well inhibit hIL-4 and hIL-13 induced proliferation of various celllines and the like, and can be used for preparing drugs for treatment of immune mediated Inflammatory reaction diseases.
Owner:SUNSHINE GUOJIAN PHARMA (SHANGHAI) CO LTD
Methods for treating eosinophilic esophagitis by administering an IL-4R inhibitor
Owner:REGENERON PHARM INC
Antibodies to interleukin-4 receptors and uses thereof
InactiveUS20050118176A1Preventing allograft rejectionGood immunosuppressive activityPeptide/protein ingredientsMicroorganism based processesIl 4 receptorMammal
Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.
Owner:IMMUNEX CORP
Methods for Treating Atopic Dermatitis by Administering an IL-4R Antagonist
InactiveUS20170333557A1Reduce dependenceReduce dosageOrganic active ingredientsPeptide/protein ingredientsAtopic dermatitisBiomarker (petroleum)
Owner:REGENERON PHARM INC
Methods for treating or preventing asthma by administering an IL-4R antagonist
ActiveUS10137193B2Reduce dependenceOrganic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntagonistAntibody
The invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods featured in the invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.
Owner:REGENERON PHARM INC +1
Methods for Treating Severe Atopic Dermatitis by Administering an IL-4R Inhibitor
ActiveUS20180078603A1Reduce dependenceReduce the amount requiredPeptide/protein ingredientsImmunoglobulins against cytokines/lymphokines/interferonsWhole bodySevere atopic dermatitis
The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody. In certain embodiments, the methods of the present invention are used to treat severe AD in a patient whose disease is not controlled with systemic therapy (e.g., cyclosporine A) or when such therapy is inadvisable.
Owner:SANOFI BIOTECH SAS +1
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor
ActiveUS10392439B2Improve efficacyImprove securityPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsRegimenAllergic reaction
The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and / or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4Rα) antagonist such as an anti-IL-4Rα antibody.
Owner:REGENERON PHARM INC
Methods for treating skin infection by administering an IL-4R antagonist
ActiveUS20150246973A1Reduce sensitivityReduce colonizationAntibacterial agentsOrganic active ingredientsCvd riskAntagonist
The present invention provides methods for treating, preventing or ameliorating skin infections, including bacterial and viral infections. In certain embodiments, the invention provides methods to reduce skin infection in a patient with atopic dermatitis (AD). Also provided are methods for improving skin barrier function, and methods for reducing the risk of inflammation due to microbial infection in a patient in need thereof. The methods of the present invention comprise administering to a patient in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.
Owner:REGENERON PHARM INC +1
Methods for Treating Allergy and Enhancing Allergen-Specific Immunotherapy by Administering an IL-4R Inhibitor
ActiveUS20180094069A1Improve efficacyImprove securityPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsRegimenAllergic reaction
The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and / or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4Rα) antagonist such as an anti-IL-4Rα antibody.
Owner:REGENERON PHARM INC
Methods for preventing or treating allergy by administering an il-4r antagonist
ActiveUS20190183973A1Treat and reduce and prevent allergy and allergen sensitizationPeptide/protein ingredientsPharmaceutical delivery mechanismDiseaseAtopic dermatitis
The present invention provides methods for preventing or treating allergy. Also provided are methods for reducing the susceptibility to an allergen in a subject in need thereof. In certain embodiments, the subject has a disease or disorder selected from the group consisting of atopic dermatitis, asthma, allergic rhinitis, and eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.
Owner:REGENERON PHARM INC +1
Methods for Treating Allergy and Enhancing Allergen-Specific Immunotherapy by Administering an IL-4R Inhibitor
ActiveUS20180094070A1Improve efficacyImprove securityPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsRegimenAllergic reaction
Owner:REGENERON PHARM INC
Methods for treating skin infection by administering an IL-4R antagonist
ActiveUS10370449B2Reduce sensitivityReduce colonizationAntibacterial agentsAntipyreticCvd riskAntagonist
The present invention provides methods for treating, preventing or ameliorating skin infections, including bacterial and viral infections. In certain embodiments, the invention provides methods to reduce skin infection in a patient with atopic dermatitis (AD). Also provided are methods for improving skin barrier function, and methods for reducing the risk of inflammation due to microbial infection in a patient in need thereof. The methods of the present invention comprise administering to a patient in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.
Owner:REGENERON PHARM INC +1
Methods for treating or preventing asthma by administering an il-4r antagonist
ActiveUS20190169299A1Improving allergic rhinitis-related quality of lifeImprove the quality of lifeOrganic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntagonistAntibody
The invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods featured in the invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.
Owner:REGENERON PHARM INC +1
Methods for treating or preventing asthma by administering an il-4r antagonist
ActiveUS20150246119A1Reduce morbidityReduce dependenceOrganic active ingredientsBiocideAntagonistAntibody
The invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods featured in the invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.
Owner:REGENERON PHARM INC +1
Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
ActiveUS9487590B2Reduce capacityImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntibodyInterleukin-4 receptor
The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to interleukin-6 receptor (IL-6R), and to methods of making and using these anti-IL-6R activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
Owner:CYTOMX THERAPEUTICS
Methods for treating atopic dermatitis by administering an il-4r inhibitor
ActiveUS20190345253A1High unmet medical needTreatment safetyImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsSevere atopic dermatitisAD - Atopic dermatitis
The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody.
Owner:REGENERON PHARM INC
Urine protein marker for chronic pancreatitis and application thereof
The present application relates to urinary protein markers for chronic pancreatitis and uses thereof. Specifically, this application relates to the use of urine protein markers obtained by using chronic pancreatitis disease models and mass spectrometry analysis in the early diagnosis of human chronic pancreatitis disease and the use of disease course monitoring. The urine protein markers are selected from Igγ‑1 chain C domain, nucleonectin‑2, beta‑2‑microglobulin, interleukin‑4 receptor alpha subunit, phosphoglycerate mutase 1, dipeptidyl peptidase 2, secreted pyrophosphoprotein 24, glycans Core protein, endothelial cell selective adhesion molecule, nestin-2, serum amyloid substance p, nerve cell adhesion molecule 1, etc. In this application, the obtained differential protein in urine provides a non-invasive and convenient option for early diagnosis and subsequent treatment of chronic pancreatitis.
Owner:BEIJING NORMAL UNIVERSITY
Chimeric Antigen Receptors
ActiveUS20180037630A1Polypeptide with localisation/targeting motifImmunoglobulin superfamilyAntigenIntracellular signalling
Disclosed herein are chimeric antigen receptors (CARs) comprising an intracellular segment comprising an interleukin receptor chain, a JAK-binding motif, a Signal Transducer and Activator of Transcription (STAT) 5 association motif and / or a CD3ζ intracellular signaling domain comprising an exogenous STAT3 association motif, as well as cells and 5 compositions comprising said CARs and uses thereof.
Owner:UNIV HEALTH NETWORK +1
Liquid composition comprising antibody of human interleukin-4 receptor alpha
ActiveCN111686247AHigh viscosityLow viscosityAntipyreticAnalgesicsHypodermoclysisSubcutaneous injection
The invention discloses a liquid composition comprising an antibody of human interleukin-4 receptor alpha. The liquid composition comprises the antibody at a concentration of 50-200 mg / ml, a buffer agent, a protective agent and a surfactant, wherein the buffer agent, the protective agent and the surfactant serve as auxiliary materials, and the liquid composition has pH of 5.4 to 6.4. When the pharmaceutical composition is used for subcutaneous injection or intravenous injection, the high-dose antibody can be provided, the administration requirement is met, and the curative effect of a medicineis improved.
Owner:SUZHOU CONNECT BIOPHARMACEUTICALS LTD
sil-4r-nap (soluble interleukin-4 receptor-neutrophil-activating protein) fusion gene
InactiveCN103923935AEasy to buildContinue to express excellentGenetic material ingredientsRespiratory disorderHelicobacter pyloriNeutrophil granulocyte
The invention relates to the field of genes, and provides a fusion gene which is used for resisting asthma. The gene comprises a fragment (a) coding a soluble interleukin-4 receptor (sIR-4R) and a fragment (b) coding a helicobacter pylori neutrophil-activating protein (HP-NAP). The gene can be connected to a vector to achieve a good effect on resisting asthma.
Owner:ZHENGZHOU UNIV
IL-4R antagonist and microorganism for generating the IL-4R antagonist
The invention relates to a new interleukin-4 receptor (IL-4R) antagonist (shown in formula I) and a pharmaceutical composition containing the antagonist. The invention also relates to an application of the IL-4R antagonist in preparing medicines for treating asthma or tumor. The invention further relates to microorganism for generating the new IL-4R antagonist (shown in formula I) and a method for preparing the new IL-4R antagonist by using the microorganism.
Owner:MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI
Interleukin-4 receptor-binding fusion proteins and uses thereof
ActiveUS20160237135A1Enhance cell viabilityIncreased activationSenses disorderNervous disorderWhite blood cellInterleukin 5
Owner:MEDICENNA THERAPEUTICS +1
Method for detecting in-vitro activity of recombined human interleukin-12 by using cell with interleukin-12 receptor and application
InactiveCN103837687AUnlimited number of passagesEasy to trainBiological material analysisBiological testingProtein insertionWhite blood cell
The invention discloses a method for detecting the in-vitro activity of recombined human interleukin-12 by using a cell with an interleukin-12 receptor and application. The method comprises the following steps of (1) taking out the frozen cell with the interleukin-12 receptor from a liquid nitrogen tank, and performing recovery activation cultivation till the logarithm growth period is reached; (2) inducing the cell with the interleukin-12 receptor through a recombined human interleukin-12 standard substance under different concentrations to generate gamma interferon to obtain the concentration value ED50s of the recombined human interleukin-12 standard substances; (3) inducing the cell with the interleukin-12 receptor through a recombined human interleukin-12 protein to be detected under different concentrations to generate the gamma interferon to obtain a concentration value ED50r of the recombined human interleukin-12 protein to be detected; and (4) obtaining the in-vitro activity Pr of the recombined human interleukin-12 protein to be detected according to a formula Pr=Ps*ED50s / ED50r.
Owner:QINGDAO KANGLITAI PHARMA
Pharmaceutical composition for treating or preventing obstructive sleep apnea
InactiveCN108339118AImprove night sleep snoringImprove apnea frequencyVertebrate antigen ingredientsAntibody ingredientsAntigenAntigen Binding Fragment
The invention discloses an antagonist or antibody of an interleukin-4 receptor (IL-4R) and an antigen-binding fragment thereof and / or a use of an antagonist or antibody of an interleukin-6 (IL-6) andan antigen-binding fragment thereof in preparation of a pharmaceutical composition for treating or preventing obstructive sleep apnea. The invention also discloses a pharmaceutical composition for treating or preventing obstructive sleep apnea. The active ingredients of the drug comprise an antagonist of an interleukin-4 receptor (IL-4R) or its antibody and antigen-binding fragment, or an antagonist or antibody of an interleukin-6 (IL-6) and an antigen-binding fragment thereof.
Owner:REYOUNG SUZHOU BIOLOGY SCI & TECH CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com